In a report issued on July 1, Thomas Smith from SVB Securities maintained a Buy rating on Celldex (CLDX – Research Report), with a price target of $68.00. The company's shares closed last Friday at $22.70, close to its 52-week low of $19.85. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -30.5% and a 16.8% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celldex with a $70.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-celldexs-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Celldex Therapeutics Charts.
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Celldex Therapeutics Charts.